Bamlanivimab use in mild-to-moderate COVID-19 disease: A matched cohort design.

Christopher J DestacheSarah J AuritDavid SchmidtLaura Peet ErkesMaureen TierneyRenuga Vivekanandan

Published in: Pharmacotherapy (2021)

BAM infusion for mild-to-moderate SARS-CoV-2 infection in outpatients significantly prevented subsequent ED visits, hospitalizations, and death from SARS-CoV-2.

Keyphrases

sars cov
respiratory syndrome coronavirus
coronavirus disease
emergency department
low dose